17βH-Neriifolin Improves Cardiac Remodeling Through Modulation of Calcium Handling Proteins in the Heart Failure Rat Model

Guardado en:

Detalles Bibliográficos
Publicado en:	Biomedicines vol. 13, no. 9 (2025), p. 2115-2131
Autor principal:	Rajasegar, Anamalley
Otros Autores:	Yusof, Kamisah, Yunos Nurhanan Murni, Zainalabidin Satirah
Publicado:	MDPI AG
Materias:	St Louis Missouri Malaysia Basel Switzerland Switzerland Selangor Malaysia United States > US Digoxin Brain natriuretic peptide Hypertrophy Na+/K+-exchanging ATPase Software Na+/Ca2+ exchanger Glycosides Thoracic surgery Endoplasmic reticulum Heart failure Toxicity Laboratories EKG Calcium (intracellular) Troponin T Animal models Heart rate Proteins Calcium (reticular) Herbivores Cardiac arrhythmia Cardiomyocytes Ca2+-transporting ATPase Blood pressure Congestive heart failure Troponin Structure-function relationships Cardiac function Cardiac glycosides
Acceso en línea:	Citation/Abstract Full Text + Graphics Full Text - PDF
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Descripción
Resumen:	Background: Cardiac glycosides such as digoxin have been commonly used for patients with heart failure; however, their toxicity remains a main concern. 17βH-neriifolin (SNA209), a cardiac glycoside compound, has been recently isolated from Ceberra odollum Gaertn and was shown to improve the heart’s pumping ability in failing hearts ex vivo. Thus, this study aimed to investigate the potential use of SNA209 as a treatment for isoprenaline (ISO)-induced heart failure in rats. Methods: Forty male Wistar rats were randomly divided into five groups. Heart failure was induced by isoprenaline (ISO, 10 mg/kg/s.c) for 14 days daily, followed by SNA209 treatment (5 mg/kg; p.o) for another 14 days daily. Control rats were given saline as a vehicle for ISO and DMSO as a vehicle for SNA209. Results: Systolic and diastolic blood pressure (SBP and DBP) in all ISO-treated groups were significantly increased compared to the control group (p < 0.05), and SNA209 treatment managed to reduce the SBP and DBP. Additionally, SNA209 treatment significantly increased the heart rate and normalized the ECG parameters in ISO-treated rats. Pro-B-type natriuretic peptide and troponin T level, a cardiac injury markers, was remarkably reduced by SNA209 in the ISO-treated group. Cardiac hypertrophy was evident in increased cardiomyocyte size in ISO groups; however, SNA reduced the cardiomyocyte size. The left ventricular developed pressure (LVDP) in ISO treated with SNA209 was significantly raised, indicating a chronotropic effect. Cardiac Na+/K+-ATPase expression of the α1 subunit, sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a (SERCA2a), and sodium–calcium exchanger subunit were significantly increased in the SNA treatment groups. Conclusions: The SNA 209 treatment improved cardiac function and structure, likely via modulating intracellular calcium management, so underscoring its potential as an adjuvant therapy for heart failure.
ISSN:	2227-9059
DOI:	10.3390/biomedicines13092115
Fuente:	Biological Science Database